Fifth Lane Capital’s Cardlytics CDLX Stock Holding History

Fifth Lane Capital’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$24.3K	–	123
2025 Q3	$24.3K	Buy	+1,000	New	+$16.7K	0.02%	98

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fifth Lane Capital's CDLX Position: Q4 2025 in Review

Fifth Lane Capital sold out of Cardlytics (CDLX) in Q4 2025, closing a stake of 1,000 shares — an estimated $24.3K sold.

Fifth Lane Capital first reported a position in CDLX in Q3 2025 and held it in 1 quarter. The position peaked at $24.3K in Q3 2025. 70 funds tracked by Wall St. Rank hold CDLX as of Q4 2025.

Fifth Lane Capital reported no remaining Cardlytics position as of Q4 2025 after selling out during the quarter.
Fifth Lane Capital sold 1,000 Cardlytics shares in Q4 2025, an estimated $24.3K.
Fifth Lane Capital first reported a position in Cardlytics in Q3 2025 and held it in 1 quarter.
Fifth Lane Capital's Cardlytics position peaked at $24.3K in Q3 2025.
70 funds tracked by Wall St. Rank held Cardlytics as of Q4 2025.

Based on Fifth Lane Capital's 13F filing for Q4 2025, filed 13 Feb 2026.